The truth is, there's no one right or wrong answer here
At 52 weeks, patients previously treated with tirzepatide maintained 74.7% of prior weight loss with orforglipron versus 49.2% with placebo, while those previously treated with semaglutide maintained 79.3% of prior weight loss with orforglipron versus 37.6% with placebo
All findings referenced are from peer-reviewed preclinical studies
Dangol, S., Chen, Y., Hwang, B
Schedule shape Typical published research planning splits a daily total into one or two doses
Pediatr Allergy Immunol 29:789800 Sakoda CPP, de Toledo AC, Perini A, Pinheiro NM, Hiyane MI, Grecco SDS, de Ftima Lopes Calvo Tibrio I, Cmara NOS, de Arruda Martins M, JHG L, Righetti RF, Prado CM (2016) Sakuranetin reverses vascular peribronchial and lung parenchyma remodeling in a murine model of chronic allergic pulmonary inflammation